Deutsche Bank AG Acquires 97,318 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Deutsche Bank AG boosted its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 304.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,319 shares of the company’s stock after purchasing an additional 97,318 shares during the period. Deutsche Bank AG owned about 0.16% of Tenaya Therapeutics worth $185,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in Tenaya Therapeutics by 61.9% in the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares in the last quarter. Hsbc Holdings PLC bought a new position in Tenaya Therapeutics in the fourth quarter valued at $45,000. Northern Trust Corp grew its position in Tenaya Therapeutics by 6.2% in the fourth quarter. Northern Trust Corp now owns 472,479 shares of the company’s stock valued at $676,000 after purchasing an additional 27,632 shares in the last quarter. Spire Wealth Management bought a new position in Tenaya Therapeutics in the fourth quarter valued at $53,000. Finally, Sei Investments Co. bought a new position in Tenaya Therapeutics in the fourth quarter valued at $100,000. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Price Performance

Shares of TNYA opened at $0.46 on Tuesday. The firm has a 50-day moving average of $0.47 and a 200-day moving average of $1.17. Tenaya Therapeutics, Inc. has a one year low of $0.36 and a one year high of $4.29. The company has a market cap of $74.83 million, a PE ratio of -0.32 and a beta of 2.99.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). Analysts expect that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Chardan Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Finally, Morgan Stanley decreased their price objective on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $6.25.

Insider Transactions at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was bought at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the purchase, the insider now owns 49,313,559 shares in the company, valued at $34,519,491.30. This represents a 262.62% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 27,137 shares of company stock worth $13,902. 48.65% of the stock is owned by insiders.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.